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ml] (p = 0.12), losing its basal significance. FABP4 may be 
a marker of psoriasis, and FABP3 may be associated with 
inflammation or liver disorders in psoriatic patients. FABP 
do not appear to be useful for determining disease severity 
or the effectiveness of antipsoriatic treatment.
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Abstract Psoriasis is associated with metabolic syndrome 
and cardiovascular disease. Fatty acid-binding proteins 
(FABP) have been recognized as predictors of these sys-
temic disorders. The aim of this study was to assess cor-
relations between levels of serum heart and adipocyte 
fatty acid-binding proteins (FABP3, FABP4) and disease 
severity, indicators of inflammation or metabolic distur-
bances, and topical treatment in psoriatic patients. Thirty-
seven patients with relapse of plaque-type psoriasis and 
16 healthy volunteers were recruited. Blood samples were 
collected before and after 14 days of therapy. Serum FABP 
concentrations were examined by enzyme-linked immu-
nosorbent assay for correlation with Psoriasis Area and 
Severity Index (PASI), body mass index (BMI), inflam-
matory or metabolic parameters, and treatment used. The 
median FABP4 serum levels were significantly increased 
(p = 0.038) in psoriatic patients, while FABP3 levels did 
not differ (p = 0.47) compared to the controls. No sig-
nificant correlations were noted between the proteins and 
PASI, C-reactive protein (CRP), BMI, or levels of glu-
cose or lipids. FABP3 significantly correlated with white 
blood count (p = 0.03) and aspartate aminotransferase 
(p = 0.04). After topical treatment, there was no significant 
change in serum FABP3 [11.5 (4.9–30.3) vs. 12.9 (3.5–
30.3) ng/ml] (p = 0.96), whereas FABP4 was decreased 
[27,286 (20,344–32,257) vs. 23,034 (18,320–29,874) pg/
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RBC  Red blood count
RBP-4  Retinol-binding protein 4
SR  Sedimentation rate
TAG  Triacylglycerol
TNF-α  Tumor necrosis factor-α
VEGF  Vascular endothelial growth factor
WBC  White blood cell
Introduction
Psoriasis is a chronic inflammatory dermatosis with a mul-
tifactorial pathogenesis, affecting over 2% of the world’s 
population. Recently it has been considered as a systemic 
disorder closely associated with coronary artery disease 
(CAD), hypertension, diabetes mellitus (DM), obesity, 
metabolic syndrome (MS) and atherosclerosis [1, 2]. Pso-
riatic patients live on average 5 years less than the general 
population, which is due to increased risk of myocardial 
infarction (MI) and thromboembolic events [3]. The risk 
of developing DM, obesity and MS is more than double, 
occurring in over 40% of psoriatic patients [4]. Com-
mon links between psoriasis and its comorbidities mainly 
involve the chronic inflammation that emerges from meta-
bolic tissues (metaflammation), genetic basis, similar path-
ways of immune disorders, and bioactive substances syn-
thesized and secreted by adipose tissue [4–6]. Numerous 
published studies, as well as ours, have demonstrated the 
potential role of various adipokines in the development of 
psoriasis and its comorbidities [5, 7].
Lipids, such as fatty acids (FA) and their derivatives, 
perform various biological functions, including their role 
in energy homeostasis, the formation of substrates for cell 
membranes, and signaling molecules in inflammatory and 
metabolic pathways [8]. Disturbances in lipid homeostasis 
can lead to numerous common disorders including obesity, 
insulin resistance (IR), DM, cardiovascular disease, and 
even skin disorders [9, 10]. Fatty acids, which constitute 
about 15% of lipids in the stratum corneum, participate in 
maintaining the permeability of the epidermis, for example, 
by stimulating acidification of the horny layer. Research 
has shown that deviations in FA composition in keratino-
cytes may be involved in the pathogenesis of inflammatory 
dermatosis such as atopic dermatitis or psoriasis [11]. FA 
shifted to long-chain fatty acids (LCFA) are transported by 
certain proteins to various tissues, where they are metabo-
lized, stored or utilized [9]. Fatty acid-binding proteins 
(FABP), first identified in 1972, are a 14–15 kDa family 
of cytosol proteins involved in active regulation of lipid 
trafficking and the protection of organisms against harm-
ful accumulation of LCFA [8, 10, 11]. To date, at least 
nine isoforms have been identified, and they have been 
named based on the tissues in which they are prominently 
expressed or those that actively participate in lipid metabo-
lism: liver, intestines, heart, adipose tissue, epidermis, ileus, 
brain, myelin and testis. FABP isoforms are thought to be 
useful indicators of organ damage and to play an important 
role in the development of a number of systemic diseases. 
FABP1 (liver FABP), present mainly in hepatocytes and 
excreted by the kidneys, indicates acute kidney damage and 
liver disorders, while the ileal isoform may be associated 
with ileitis or IR [10].
Epidermal fatty acid-binding protein 5 (FABP5), with its 
gene located at chromosome 8q21.13, is mostly expressed 
in epidermal cells, but also in other tissues including the 
brain, kidney, liver, lungs, and testis and in adipose tissue. 
Various studies have stressed its role in regulating insulin 
sensitivity, lipid homeostasis, MS, skin barrier conditions, 
and even nerve regeneration [8, 10, 12, 13]. FABP5 is 
also called psoriasis-associated FABP (PA-FABP), which 
reflects its already proven links with this dermatosis [12, 
13]. Some studies have indicated that FABP5 modulates 
the differentiation of keratinocytes and is highly over-
expressed in psoriatic plaques or atopic dermatitis [12, 13].
Heart-type FABP (FABP3), with the encoding gene 
located on chromosome 1p33–p31, is expressed mainly 
in the heart, skeletal muscle, brain, mammary glands and 
brown adipose tissue. FABP3 is superior to troponin as a 
highly sensitive marker of acute myocardial infarction and 
predictor of heart failure in patients with MS, which is 
strongly associated with psoriasis [8, 10]. FABP3 also par-
ticipates in thermoregulation and affects glucose homeosta-
sis and cardiac sufficiency [9, 10]. A precise role of FABP3 
in other tissues and the development of certain diseases is 
still largely unknown.
Adipocyte fatty acid-binding protein (FABP4), also 
termed adipocyte protein 2 (aP2), is an adipokine synthe-
sized and released predominantly from adipocytes and, to 
a lesser extent, produced in macrophages and endothelial 
cells [6, 14]. FABP4, with a molecular mass of 14.6 kDa 
and 132 amino acids, accounts for up to 6% of total cellu-
lar proteins. The gene encoding this adipokine is located on 
chromosome 8q21. Elevated levels of FABP4 are closely 
linked with the development of obesity, IR, DM, hyper-
tension, CAD and atherosclerosis [10, 14, 15]. Studies in 
humans have shown that a genetic variant at the FABP4 
locus reduced the risk for atherosclerosis, diabetes and cor-
onary heart disease [16, 17], and reduced FABP4 expres-
sion in adipose tissue was related to lower risk for CAD 
and DM [16]. Several studies have proved that increased 
circulating FABP4 levels are a promising biomarker pre-
dicting heart failure, stroke, and prognosis and mortality in 
patients with end-stage renal disease, CAD or other critical 
illnesses [6, 14, 15, 20, 21].
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Another possible role of FABP4 in psoriasis is evident in 
the influence on MS, which is strongly associated with pso-
riasis. FABP4 is an independent predictive marker for the 
development of MS, as was shown in a 5-year prospective 
study and in a study of Korean boys [18, 19].
A further link between FABP4 and psoriasis may be a 
correlation with tumor necrosis factor-α (TNF-α), which is 
one of the major cytokines involved in the pathogenesis of 
this dermatosis. FABP4-deficient macrophages and treat-
ment with TNF-α inhibitors was found to lead to a sig-
nificant reduction in cytokine levels [14]. FABP4 has been 
linked to angiogenesis and vascular endothelial growth fac-
tor (VEGF), which are also highly disturbed in psoriasis [6].
In summary, FABP4 and FABP3 may play a pivotal role 
in numerous disorders, including obesity, atherosclerosis, 
MS, IR and CAD, which are closely associated with pso-
riasis. The actual role of the FABP in the pathogenesis of 
the dermatosis and its metabolic comorbidities has not yet 
been investigated. The aim of this study, therefore, was to 
evaluate serum FABP4 and FABP3 levels in patients with 
plaque-type psoriasis, and the relationship between these 
FABP and the duration and activity of the disease as well as 
the inflammatory or metabolic markers, selected adipokines 
and changes after standard topical therapy. A second objec-
tive of the study was to assess whether FABP3 and FABP4 
could be useful for predicting the risk of cardiovascular 
disorders or metabolic diseases in patients with psoriasis.
Materials and Methods
In this prospective study, 37 patients (15 women and 22 men) 
aged 19–84 years (mean 48.6 ± 2.4) with flare of plaque-
type psoriasis were recruited in the Department of Dermatol-
ogy and Venereology at the Medical University of Bialystok. 
The exclusion criteria were other forms of psoriasis or any 
chronic inflammatory, autoimmune or metabolic diseases. 
None of the patients was under dietary restrictions, and no 
patients received any chronic systemic or topical treatment for 
1 month prior to enrollment. The Psoriasis Area and Severity 
Index (PASI) score was determined by the same investiga-
tor in all patients, with PASI scoring as follows: <10 points 
indicated mild psoriasis; 10—20 indicated moderate psoriasis; 
>20 indicated severe disease. Body mass index (BMI) was 
calculated as weight/height2 (kg/m2). Blood samples were col-
lected before initiation and after 2 weeks of topical treatment 
with 5% salicylic acid ointment and 0.3% anthralin. FABP4 
and FABP3 serum concentrations were evaluated in relation to 
normal values collected from 16 healthy age-, sex- and BMI-
matched volunteers. The study was approved by the bioethics 
committee of the Medical University of Bialystok, and all par-
ticipants provided written informed consent before enrollment.
Serum Collection
Blood samples were collected from the study and control 
groups using Vacutainer tubes, and were left for 30 min to 
allow clotting before centrifugation for 15 min at 1000g, 
after which the serum was separated and stored at −80 °C 
until use. FABP3 and FABP4 levels were measured using 
the Quantikine® enzyme immunoassay kit (R&D Sys-
tems, Minneapolis, MN, USA). The limit of detection for 
FABP3 was 0.273 ng/ml and for FABP4 was 13.3 pg/ml, 
and the standard curve ranges were 0.625–40 ng/ml and 
31.2–2000 pg/ml, respectively. Optical density was read at 
a wavelength of 450 nm. The concentrations were assessed 
by interpolation from calibration curves prepared with 
standard samples provided by the manufacturer.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 
5 (GraphPad Software, La Jolla, CA, USA) and Statis-
tica 10.0 (StatSoft, Inc., Tulsa, OK, USA). A value of 
p < 0.05 was considered statistically significant. Data are 
presented as median (IQR, interquartile range), percentage 
and mean ± standard deviation (±SD) when appropriate. 
The following non-parametric (distribution-free) tests were 
applied: Mann–Whitney U test for comparisons between 
psoriasis and control groups, Kruskal–Wallis analysis of 
variance (ANOVA) for comparisons of multiple groups 
(PASI groups), and Spearman’s rank test for correlations 
analyses.
Results
Clinical, demographic and laboratory data concerning 
the study group are summarized in Table 1. A total of 37 
patients with active plaque-type psoriasis (15 women, 
22 men; mean age 48.6 ± 2.4 [19–84] years) and 16 age- 
and sex-matched healthy individuals were enrolled in the 
study. Disease duration ranged from 1 to 55 years (mean, 
17.4 ± 1.8 years), and the relapse duration ranged from 
1 to 2 years (mean, 4.4. ± 0.9 years). The median BMI 
value was 27 kg/m2 (24–31), and the median basal PASI 
score was 18.8 (10.7–21.8). In the studied group, 7 patients 
(18.9%) had mild psoriasis (PASI <10), 16 (43.2%) had 
moderate disease (PASI 10–20), and 14 patients (37.8%) 
were diagnosed with a severe form (PASI >20). The 
median FABP3 concentration in psoriatic patients of 12.57 
(4.23–29.6) ng/ml was not statistically different from that 
of healthy individuals at 7.8 (0.6–28) ng/ml (p = 0.47; 
Fig. 1). The median level of FABP3 in patients with 
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moderate psoriasis, at 19.1 (4.5–31.1) ng/ml, was almost 
2.5 times as high as that of the controls, but did not reach 
statistical significance (p = 0.19; Table 2). The lowest 
FABP3, 6.8 (2.1–30.0) ng/ml and slightly lower than that 
of the controls, was noted in the group with severe psoriasis 
(p = 0.96), but it was not statistically significant (Table 2). 
The median FABP4 level, 27,286 (20,344–32,257) pg/ml, 
was significantly higher (p = 0.038) than that of the con-
trols at 21,445 (17,449–24,725) pg/ml (Fig. 2). FABP4 lev-
els based on psoriasis activity were significantly higher in 
the group with PASI <10 (p = 0.002) compared to the con-
trols (Table 2). Serum FABP4 and FABP3 levels showed no 
correlation with PASI severity score (p = 0.17, p = 0.59, 
respectively; Figs. 3, 4). We did not find any relation 
between evaluated FABP and age of the patients, or disease 
or relapse duration (Table 3). With regard to differences 
by sex in the study group, FABP3 levels were significantly 
higher in men than in women (p = 0.03; Fig. 5), with 
median serum FABP3 concentration in men of 27.07 (5.68–
33.77) nearly four times as high as that in women, at 7.13 
(3.5–14.38). In terms of links with selected proteins, a sig-
nificant negative correlation was observed between FABP3 
and retinol-binding protein 4 (RBP-4) (p = 0.02; Table 3). 
No links between FABP and other adipokines such as adi-
ponectin, leptin or lipocalin-2 were noted (Table 3). In 
evaluating relations with basic inflammatory indices, only 
FABP3 and white blood cell (WBC) count showed a signif-
icant positive correlation (p = 0.03; Table 3). With regard 
to liver enzymes, FABP3 was significantly positively 
Table 1  Characteristics of 
study population (median 
25–75% CI, SD, mean)
Characteristic Psoriasis patients, n = 37 Control group, n = 16
Median (CI) SD Mean Median (CI) SD Mean
SR (mm/h) 16 (7–36) 20.3 22.9 – – –
CRP (mg/l) 3.4 (2.1–15.6) 29 14.3 1.9 (1.2–3.0) 1.4 2.2
WBC (×103/ml) 7.3 (6.3–8.7) 2.3 7.7 7.3 (6.3–8.0) 0.9 7.3
PLT (×103/ml) 203 (164–265) 68.6 215 267 (249–301) 48.5 275
Glucose level 89 (77–94) 12 87 88 (80–99) 11.2 88
BMI (kg/m2) 27 (24–31) 5.2 28 22 (20–24) 2.7 23
Sex (male/female) 37 (22/15) 16 (7/9)
PASI before treatment 18.8 (10.7–21.8) 7.4 17 – – –
PASI after treatment 8.4 (4.7–12.3) 4.4 8.4 – – –
Fig. 1  Comparison of serum FABP3 concentrations between patients 
and controls
Table 2  Serum FABP3 and FABP4 concentrations in psoriatic patients before treatment by PASI score in three groups (<10, 10–20, >20) com-
pared to the controls
Statistical analysis using the Mann–Whitney U test, median (25–75% CI)
* Statistically significant (p < 0.05)
Controls Psoriatic patients
<10 10–20 >20
n = 7 n = 16 n = 14
FABP3 (ng/ml) 7.8 (0.6–28) 11.5 (4.2–31.8) 19.1 (7.5–31.1) 6.8 (2.1–30.0)
p value (vs. controls) 0.77 0.19 0.96
FABP4 (pg/ml) 21,445 (17,449–24,725) 32,257 (27,389–39,328) 26,518 (19,332–32,205) 23,085 (19,024–31,091)
p value (vs. controls) 0.002* 0.14 0.35
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correlated with aspartate aminotransferase (AST) before 
and after treatment (p = 0.04, p = 0.025, respectively), and 
FABP4 with alanine aminotransferase (ALT) after treat-
ment (p = 0.01; Table 3). No statistically significant cor-
relations with FABP were noted for any of the investigated 
lipid parameters, either for glucose levels or BMI, aside 
from a significant positive relationship between FABP4 
and BMI after treatment (p = 0.04; Table 3). We divided 
our psoriatic patients into four groups based on BMI, as 
follows: group 0, normal weight (BMI 18.5–24.9), 10 
patients; group 1, overweight (BMI 25–29.9), 14 patients; 
group 2, obesity grade I (BMI 30–34.99), 9 patients; and 
group 3, obesity grade II (BMI 35–39.9), 4 patients. Serum 
FABP3 levels in normal-weight (group 0) patients were 
significantly correlated with those who were overweight 
(group 1; p = 0.04), but not with controls or other groups 
(Fig. 6). FABP4 concentrations in overweight individu-
als (BMI 25–29.9) were significantly higher than those in 
psoriatic patients of normal weight (p = 0.03) and controls 
(0.006; Fig. 7).         
After 14 days of topical therapy with 5% salicylic acid 
ointment and 0.3% anthralin, skin lesions in all patients 
improved. The median total PASI score after therapy 
decreased to 8.4 (4.7–12.3) from the basal PASI of 18.8 
(10.7–21.8; Table 1). There was no change in median 
FABP3 levels after therapy (p = 0.5), with levels after 
treatment remaining comparable to those before treatment 
and to those of the controls (Table 4). Similar to the analy-
sis of the whole study population, the assessments carried 
out among groups with different disease severity showed 
no significant influence of therapy on serum FABP3 con-
centrations (Table 5). There was no meaningful change in 
median FABP4 concentration after topical therapy. How-
ever, there was a non-significant reduction (p = 0.61) rela-
tive to controls, losing statistical significance from before 
treatment (p = 0.038; Table 4). In patients with PASI <10, 
serum FABP4 levels were significantly decreased from lev-
els before treatment (p = 0.03; Table 5). In patients with 
mild psoriasis, FABP4 levels were significantly higher than 
those in controls before treatment (p = 0.002), but the dif-
ferences did not remain significant after therapy (p = 0.09; 
Fig. 8). There were no statistically significant differences 
in serum FABP3 or FABP4 levels after treatment based on 
severity of psoriasis (Table 6).   
Discussion
It is extremely difficult to discuss the results obtained 
in this work when, to the best of our knowledge, there is 
not a single study in the published literature regarding the 
role of the heart and adipocyte isoforms of FABP in pso-
riasis, or the relationship with antipsoriatic therapy. A few 
Fig. 2  Comparison of serum FABP4 concentrations between patients 
and controls
Fig. 3  Correlation between concentrations of serum FABP4 and 
PASI
Fig. 4  Correlation between concentrations of serum FABP3 and 
PASI
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papers have shown only the importance of FABP5 in pso-
riatic keratinocyte differentiation proving disturbances in 
fatty acid metabolism in the lesions but also in the unin-
volved skin of patients with psoriasis [13, 22]. Miyake et 
al evaluated FABP5 levels in serum and tape-stripped pso-
riatic skin [22]. Serum FABP5 levels were similar between 
patients with psoriasis and controls, and did not reflect the 
skin condition. Levels of FABP5 were statistically elevated 
in psoriatic lesions compared with uninvolved skin. Skin-
stripping FABP5 did not correlate with PASI, but was sta-
tistically associated with total erythema, induration and 
desquamation scores. The authors suggested that skin-strip-
ping FABP5 levels are related instead to local skin condi-
tion. Miyake et al. also investigated FABP5 (E-FABP) dur-
ing anti-TNF-α and narrow-band ultraviolet B (NB-UVB) 
light therapy. They noted a reduction in skin-stripping 
FABP5 levels and posited that it could be used to monitor 
Table 3  Main variables of the 
study in patients before and 
after treatment and correlations 
with serum FABP3 and FABP4 
levels
* Statistically significant correlation (p < 0.05), p values obtained by Spearman correlation
Characteristic Before treatment, r (p value) After treatment, r (p value)
FABP3 FABP4 FABP 3 FABP4
SR (mm/h) 0.156 (0.36) 0.04 (0.82) −0.197 (0.24) 0.05 (0.75)
WBC (×103/ml) 0.366 (0.03)* 0.04 (0.82) −0.191 (0.26) 0.07 (0.65)
ALT (IU/l) 0.230 (0.17) 0.14 (0.42) −0.168 (0.32) 0.41 (0.01)*
AST (IU/l) 0.333 (0.04)* 0.15 (0.38) 0.367 (0.025)* 0.06 (0.73)
PLT (×103/ml) 0.110 (0.50) 0.21 (0.22) −0.293 (0.08) 0.15 (0.37)
BMI (kg/m2) 0.260 (0.12) 0.22 (0.19) −0202 (0.23) 0.33 (0.04)*
RBC (×103/ml) 0.041 (0.80) 0.01 (0.95) 0.113 (0.50) 0.10 (0.54)
Glucose level (mg/dl) −0.0002 (0.99) 0.07 (0.68) −0.019 (0.91) 0.14 (0.39)
CRP (mg/l) 0.049 (0.77) 0.03 (0.84) 0.065 (0.70) 0.21 (0.21)
Cholesterol (mg/dl) 0.090 (0.73) 0.09 (0.73) 0.172 (0.51) 0.03 (0.89)
HDL-C (mg/dl) 0.107 (0.68) 0.36 (0.16) 0.062 (0.81) 0.46 (0.06)
LDL-C (mg/dl) 0.065 (0.80) 0.38 (0.13) 0.054 (0.84) −0.09 (0.71)
TAG (mg/dl) 0.054 (0.84) 0.06 (0.82) −0.015 (0.95) −0.29 (0.25)
Adiponectin −0.007 (0.96) −0.02 (0.91) −0.114 (0.50) −0.04 (0.77)
Leptin 0.004 (0.99) 0.11 (0.51) 0.227 (0.17) 0.16 (0.32)
RBP-4 0.067 (0.69) −0.38 (0.02)* −0146 (0.38) −0.35 (0.03)*
FABP3 – 0.15 (0.37) – 0.29 (0.08)*
FABP4 0.150 (0.37) – 0.29 (0.08)* –
Age (years) −0.001 (0.99) −0.07 (0.67) −0.040 (0.813) 0.05 (0.75)
Relapse duration (months) 0.170 (0.31) 0.18 (0.29) 0.244 (0.15) −0.01 (0.92)
Disease duration (years) −0.217 (0.20) −0.15 (0.39) 0.202 (0.23) 0.02 (0.93)
Fig. 5  Comparison of serum FABP3 concentrations in the study 
group before treatment by sex
Fig. 6  Comparison of FABP3 levels before treatment between 
groups of patients by BMI
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therapy outcome [22]. It should be noted, however, that 
these results were obtained in a very small sample—seven 
patients—treated with different methods (two patients 
with adalimumab, three with infliximab and two with NB-
UVB), rendering them very speculative.
A study by Kucharekova et al. failed to demonstrate 
upregulation of FABP5 after single use of anthralin on 
uninvolved psoriatic skin, thus refuting the thesis regarding 
the function of the protein in oxidative stress or skin barrier 
impairment caused by the topical agent [23]. In our study, 
we evaluated the influence of a longer course of therapy 
with anthralin, but on other FABP isoforms and their levels 
in serum, not in the skin.
Considering that FABP3 is a highly sensitive predictor 
of MI, especially in patients with MS, which is strongly 
linked to psoriasis, we assumed that this protein could serve 
as a marker of heart failure in patients with this dermatosis. 
Unfortunately, there was no change in serum FABP3 levels 
in our patients compared to the healthy individuals. How-
ever, the concentration was almost 2.5 times as high in per-
sons with PASI 10–20 as in controls, indicating that FABP3 
could have some relevance in patients with moderate pso-
riasis. The significant positive correlation between FABP3 
and WBC leads us to speculate that this protein could be 
an indicator of inflammation in psoriatic patients. How-
ever, no relationship with CRP was shown. A statistically 
significant association between FABP3 and AST activity 
points to some unknown link with liver function or perhaps 
non-alcoholic fatty liver disease (NAFLD) and psoriasis. 
On the other hand, the liver is involved in metabolic pro-
cesses and lipid metabolism, and our study did not show 
Fig. 7  Comparison of FABP4 levels before treatment between 
groups of patients and controls by BMI
Table 4  Serum FABP3 and 
FABP4 concentrations in 
psoriatic patients before and 
after treatment compared to the 
control group
Statistical analysis using the Mann–Whitney U test, median (25–75% CI)
* Statistically significant (p < 0.05)
Controls Psoriatic patients
Before treatment After treatment
FABP3 (ng/ml) 7.86 (0.61–28.16) 11.48 (4.96–30.33) 12.93 (3.51–30.33)
p value (vs. controls) 0.47 0.50
FABP4 (pg/ml) 21,445 (17,449–24,725) 27,286 (20,344–32,257) 23,034 (18,320–29,874)
p value (vs. controls) 0.038* 0.614
Table 5  Serum FABP3 and FABP4 concentrations in psoriatic patients before and after treatment, by PASI score in three groups (<10, 10–20, 
>20) in relation to the controls
Statistical analysis using the Mann–Whitney U test




 Before treatment 11.5 (4.2–31.8) 19.1 (7.5–31.1) 6.8 (2.1–30.0)
 After treatment 10.0 (0.6–15.8) 11.5 (3.5–32.5) 20.5 (7.8–34.7)
 p (before vs. after treatment) 0.62 0.36 0.22
FABP4 (pg/ml)
 Before treatment 32,257 (27,389–39,328) 26,518 (19,332–32,205) 23,085 (19,024–31,091)
 After treatment 25,134 (22,777–27,082) 23,187 (18,038–35,139) 19,934 (16,513–27,735)
 p (before vs. after treatment) 0.03* 0.65 0.36
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any relationship between FABP3 and indicators of meta-
bolic disorders such as glucose level, BMI, lipid profile 
or other adipokines involved in the pathogenesis of many 
common systemic diseases including psoriasis. Analysis 
of demographic features including age and the duration of 
the disease and relapse revealed no statistical correlation 
with FABP3 or FABP4. We noted significantly higher lev-
els of FABP4 in men with psoriasis compared to women. 
Pelsers et al. also found higher concentrations of the heart 
isoform of FABP in men as well as an increase with age, 
but in healthy volunteers [24]. Conversely, FABP4 seems 
to be more closely related to women and age, but it has not 
been investigated in relation to psoriasis [18, 25]. FABP4 
was not associated with sex in our study group.
Although FABP4 is the most commonly known isoform 
of FABP, no studies have investigated its role in psoriasis. 
This adipokine has been linked to IR, DM, MS, obesity, 
atherosclerosis, CAD and NAFLD. We can speculate that 
FABP4 may be a link between psoriasis and its metabolic 
comorbidities, especially because we found significantly 
increased serum concentration of this adipokine. Thus 
FABP4 could be a biomarker of psoriasis or a predic-
tor of metabolic disorders and their complications in our 
patients, particularly those with a mild type of psoriasis. In 
terms of links between inflammatory or metabolic indica-
tors and FABP4, we found no correlation with WBC, CRP 
or glucose levels aside from a positive relationship with 
BMI, which was significant only after therapy. Our results 
showed that serum FABP4 concentration was significantly 
higher in overweight patients than in normal-weight pso-
riatic patients or in controls. Surprisingly, adipokine lev-
els did not correlate with BMI or adipose tissue content 
expressed as weight. Therefore, it must be assumed that 
serum FABP4 levels in psoriatic patients are dependent 
not only on the adipose tissue content expressed by BMI, 
for example, but also on various other modified effectors 
influencing different inflammatory or immunological stim-
uli in psoriasis. As for the lipid profile, we did not observe 
statistical correlations. Several studies have noted posi-
tive correlations between FABP4 and high-density lipo-
protein (HDL) and low-density lipoprotein (LDL) choles-
terol, triacylglycerol (TAG), BMI, CRP or adiponectin and 
TNF-α [14, 18, 26]. Zhang et al. did not prove a positive 
link with BMI in individuals with chronic obstructive pul-
monary disease [25]. With respect to the relationship with 
other adipokines, no association was demonstrated in the 
present study between adiponectin and leptin, other than a 
significant inverse relationship with RBP-4. In our previous 
work, we hypothesized that RBP-4 might have a protective 
role in terms of chronic inflammation and comorbidities of 
psoriasis [7]. This adipokine has been associated in particu-
lar with IR, DM, obesity and MS or cardiometabolic risk, 
which are relevant in psoriasis [27]. With regard to the neg-
ative relation between RBP-4 and FABP4, we can assume 
that the latter could serve as an indicator of comorbidities 
in psoriatic patients, as its level was significantly increased 
in the study group.
In our study, after 2 weeks of topical treatment with 
keratolytic ointment and anthralin, we found no signifi-
cant influence on median serum levels of FABP in psoriatic 
patients compared to healthy individuals. However, in rela-
tion to the level of psoriasis activity, FABP4 was decreased, 
losing its basal significantly higher level in comparison to 
the controls. With regard to the impact of topical therapy 
on FABP levels by PASI score, FABP4 in patients with 
mild psoriasis lost its basal significance, but the level did 
not reach statistical significance. We can assume that, even 
though anthralin may be considered an outdated treatment, 
it may influence lipid metabolism through its impact on 
FABP4 in patients with psoriasis. The adipokine could be 
useful in determining the effectiveness of anthralin in pso-
riatic patients with a mild type of the disease.
Because FABP are responsible for the integration of 
inflammatory or metabolic processes and are strongly 
involved in the development of MS, IR, CAD and NAFLD, 
they have become a therapeutic target. Several studies have 
reported the efficacy of synthetic FABP4 inhibitors against 
the diseases mentioned above [6, 10, 14]. Good therapeutic 
effects by reducing FABP4 levels were noted with the use 
of BMS309403 FABP4-neutralizing antibodies as well as 
Fig. 8  Comparison of serum FABP4 concentrations between patients 
and controls before and after treatment, by PASI score
Table 6  Serum FABP3 and FABP4 concentrations in psoriatic 
patients after treatment, by PASI score (<10, 10–20, >20)
Statistical analysis using the Mann–Whitney U test
 Significance level p < 0.05
PASI
<10 vs. 10–20 <10 vs. >20 10–20 vs. >20
FABP3 0.48 0.11 0.32
FABP4 0.55 0.11 0.60
59Lipids (2017) 52:51–60 
1 3
other commonly used drugs such as sitagliptin, angioten-
sin II receptor blockers and omega-3 fatty acids [10, 28–
30]. These promising data enable us to draw conclusions 
regarding the potential use of drugs reducing FABP4 levels 
also for protecting patients with psoriasis from cardiovas-
cular or metabolic disorders. Looking at the possible medi-
cal insights concerning FABP, more research is needed 
to clarify the role of FABP in psoriasis or its neutralizing 
antibodies in future antipsoriatic therapy. There are some 
limitations of this study that must be considered when ana-
lyzing the data presented. The major limitation is the small 
number of patients (n = 37), although they were evaluated 
at two time points. The number of patients grouped by 
disease severity (PASI 1 n = 7, PASI 2 n = 16, PASI 3 
n = 14) is also inadequate. A larger group with mild psoria-
sis is definitely advisable for future investigations. In addi-
tion, the designation of FABP4 is indicated for comparison 
with other FABP assessed in the study. We plan to extend 
our investigation to a greater number of patients, different 
methods of treatment and further isoforms of FABP in sub-
sequent stages of our research.
Serum FABP4 levels were significantly increased in 
patients with psoriasis, indicating that this protein may be 
a marker of psoriasis and an independent predictor of the 
risk of comorbidities or complications in psoriatic patients. 
The FABP studied in this work do not appear to be use-
ful for determining the severity of psoriasis. A positive 
correlation between FABP3 and white blood count or liver 
enzyme activity points to a possible indication of inflam-
mation or a link between psoriasis and liver disorders. The 
evaluated proteins may not be helpful for monitoring the 
efficacy of standard topical treatment. In conclusion, data 
from the literature are sparse and inconsistent, and they 
refer to patients with diseases other than psoriasis, so it is 
impossible to clearly interpret our findings. However, the 
above-mentioned limitations of this study prevent us from 
drawing definitive conclusions regarding the role of FABP3 
and FABP4 as predictive factors for psoriatic patients. Nev-
ertheless, it underscores the uniqueness of the present study 
and the need for further study to determine the precise role 
of FABP4 and FABP3 in the pathogenesis of psoriasis and 
its comorbidities.
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